論文 - 詳細
| RRC ID | 38975 |
|---|---|
| 著者 | Yamashita M, Niki H, Yamada M, Mue S, Ohuchi K. |
| タイトル | Induction of nitric oxide synthase by lipopolysaccharide and its inhibition by auranofin in RAW 264.7 cells. |
| ジャーナル | Eur J Pharmacol |
| Abstract |
In RAW 264.7 cells, a murine macrophage cell line, treatment with lipopolysaccharide (1 to 10 ng/ml) stimulated production of nitric oxide (NO), which was inhibited by L-N(G)-monomethyl-L-arginine acetate, an inhibitor of NO synthase. Auranofin, an orally active chrysotherapeutic agent, also inhibited the lipopolysaccharide-induced NO production in a concentration-dependent manner (0.3 to 3 microM). Other gold salts such as aurothioglucose and aurothiomalate had no effect. Western blot analysis demonstrated that the lipopolysaccharide (10 ng/ml)-induced expression of inducible NO synthase protein was inhibited by auranofin as well as by the protein synthesis inhibitor cycloheximide. In addition, the lipopolysaccharide-induced increase in the level of mRNA for inducible NO synthase was also lowered by auranofin. Furthermore, auranofin showed no direct effect on the conversion of [3H]arginine to [3H]citrulline by the cell lysate. These findings indicate that auranofin inhibits lipopolysaccharide-induced NO production by suppressing the expression of inducible NO synthase. |
| 巻・号 | 338(2) |
| ページ | 151-8 |
| 公開日 | 1997-11-5 |
| DOI | 10.1016/s0014-2999(97)81943-7 |
| PII | S0014-2999(97)81943-7 |
| PMID | 9455997 |
| MeSH | Animals Antirheumatic Agents / pharmacology* Auranofin / pharmacology* Blotting, Western Cell Line Cell-Free System Endotoxins / antagonists & inhibitors* Endotoxins / pharmacology* Enzyme Induction / drug effects Enzyme Inhibitors / pharmacology Macrophages / drug effects Macrophages / enzymology* Mice Nitric Oxide Synthase / antagonists & inhibitors Nitric Oxide Synthase / biosynthesis* Nitric Oxide Synthase Type II Nitrites / metabolism Polymerase Chain Reaction Protein Biosynthesis RNA, Messenger / biosynthesis |
| IF | 3.263 |
| 引用数 | 14 |
| WOS 分野 | PHARMACOLOGY & PHARMACY |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 3 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | RAW 264(RCB0535) |